{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.571","upperLimit":"12.286","value":"8.9"},{"groupId":"OG001","lowerLimit":"10.857","upperLimit":"12.143","value":"12.1"},{"groupId":"OG002","lowerLimit":"10.000","upperLimit":"20.429","value":"12.4"},{"comment":"Upper confidence interval bounds were not estimable in some arms due to censoring","groupId":"OG003","lowerLimit":"11.571","upperLimit":"NA","value":"19.143"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of the first T-cell infusion to the first date of the radiological PD or death date (due to any reason), whichever event was earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel, Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.","id":"OG003","title":"Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel","reportingStatus":"POSTED","timeFrame":"From afamitresgene autoleucel infusion until first documented PD or death due to any cause, whichever comes first, or censored date.","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}